Work

Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e20545

Authors: Chul Kim, Nitin Roper, Chuong D. Hoang, Eva Szabo, Maureen Connolly, Emerson Padiernos, Aparna Hemant Kesarwala, Constance Cultraro, Maryam Waris, Shaojian Gao, Seth M. Steinberg, David T. Wong, Javed Khan, Arun Rajan, Udayan Guha

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891248095

Cites:

Cited by: 4

Related to: 10